Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by BridgeBio Pharma, Inc.

< Previous 1 2 3 4 Next >
BridgeBio to Host Investor Call to Share Topline 30-month Results from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy on July 17, 2023
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
Burjeel Holdings to Launch Rare Disease Research & Development Project ‘NADER’ in Partnership with US-based BridgeBio Pharma
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Presents Updated Six Month Results from its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia at the Endocrine Society (ENDO) 2023 Annual Conference
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual Conference
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Presents Updated Encouraging Clinical and Biomarker Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Reports First Quarter 2023 Financial Results and Business Update
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Shares Preliminary Findings on Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma to Present Preliminary Findings on its Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio to Host Investor Call to Discuss Phase 2 Cohort 5 Data for Achondroplasia on March 6, 2023
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma to Host Educational Roundtable with Esteemed Achondroplasia Expert on February 16, 2023
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma to Participate in February and March Investor Events
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma to Present at the J.P. Morgan Healthcare Conference
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma to Participate in November Investor Events
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Highlights its RAS Precision Oncology Portfolio and Shares Compelling Data from Next-generation G12C Inhibitor and Novel PI3Kα:RAS Breaker Mechanism at the Fourth RAS Initiative Symposium
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Presents Updated Positive Data from its BBP-812 Canavan Disease Gene Therapy Program at the 51st Annual Meeting of the Child Neurology Society
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.